Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
FDA panel: More data needed on effects of hep B vaccine
The FDA's Vaccines and Related Biologics Advisory Committee voted 13 to 1 in support of the efficacy of Dynavax's hepatitis B vaccine Heplisav, but questioned its safety and the insufficient information on its effects among some minorities, including Hispanics, blacks and Asians.
Or we can send an email on your behalf